China
· Delayed Price · Currency is CNY Jointown Pharmaceutical Group Statistics
Total Valuation
Jointown Pharmaceutical Group has a market cap or net worth of CNY 26.92 billion. The enterprise value is 33.14 billion.
| Market Cap | 26.92B |
| Enterprise Value | 33.14B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jun 7, 2024 |
Share Statistics
Jointown Pharmaceutical Group has 4.91 billion shares outstanding. The number of shares has decreased by -2.09% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.91B |
| Shares Change (YoY) | -2.09% |
| Shares Change (QoQ) | +12.74% |
| Owned by Insiders (%) | 2.82% |
| Owned by Institutions (%) | 14.10% |
| Float | 1.78B |
Valuation Ratios
The trailing PE ratio is 13.50 and the forward PE ratio is 11.99.
| PE Ratio | 13.50 |
| Forward PE | 11.99 |
| PS Ratio | 0.19 |
| PB Ratio | 1.18 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 85.02 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.80, with an EV/FCF ratio of 104.69.
| EV / Earnings | 16.19 |
| EV / Sales | 0.22 |
| EV / EBITDA | 6.80 |
| EV / EBIT | 8.02 |
| EV / FCF | 104.69 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.27 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 2.94 |
| Debt / FCF | 45.21 |
| Interest Coverage | 3.26 |
Financial Efficiency
Return on equity (ROE) is 7.15% and return on invested capital (ROIC) is 5.63%.
| Return on Equity (ROE) | 7.15% |
| Return on Assets (ROA) | 2.66% |
| Return on Capital (ROIC) | 5.63% |
| Revenue Per Employee | 4.96M |
| Profits Per Employee | 67,992 |
| Employee Count | 30,100 |
| Asset Turnover | 1.54 |
| Inventory Turnover | 8.06 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.39% in the last 52 weeks. The beta is 0.16, so Jointown Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -6.39% |
| 50-Day Moving Average | 5.17 |
| 200-Day Moving Average | 5.46 |
| Relative Strength Index (RSI) | 56.26 |
| Average Volume (20 Days) | 47,428,842 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jointown Pharmaceutical Group had revenue of CNY 149.20 billion and earned 2.05 billion in profits. Earnings per share was 0.41.
| Revenue | 149.20B |
| Gross Profit | 11.75B |
| Operating Income | 4.14B |
| Pretax Income | 2.90B |
| Net Income | 2.05B |
| EBITDA | 4.78B |
| EBIT | 4.14B |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 16.24 billion in cash and 14.31 billion in debt, giving a net cash position of 1.93 billion or 0.39 per share.
| Cash & Cash Equivalents | 16.24B |
| Total Debt | 14.31B |
| Net Cash | 1.93B |
| Net Cash Per Share | 0.39 |
| Equity (Book Value) | 32.81B |
| Book Value Per Share | 4.65 |
| Working Capital | 17.45B |
Cash Flow
In the last 12 months, operating cash flow was 1.29 billion and capital expenditures -974.29 million, giving a free cash flow of 316.59 million.
| Operating Cash Flow | 1.29B |
| Capital Expenditures | -974.29M |
| Free Cash Flow | 316.59M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 7.88%, with operating and profit margins of 2.77% and 1.37%.
| Gross Margin | 7.88% |
| Operating Margin | 2.77% |
| Pretax Margin | 1.95% |
| Profit Margin | 1.37% |
| EBITDA Margin | 3.20% |
| EBIT Margin | 2.77% |
| FCF Margin | 0.21% |
Dividends & Yields
This stock pays an annual dividend of 0.19, which amounts to a dividend yield of 3.51%.
| Dividend Per Share | 0.19 |
| Dividend Yield | 3.51% |
| Dividend Growth (YoY) | -9.70% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 77.98% |
| Buyback Yield | 2.09% |
| Shareholder Yield | 5.60% |
| Earnings Yield | 7.41% |
| FCF Yield | 1.18% |
Stock Splits
The last stock split was on June 7, 2024. It was a forward split with a ratio of 1.29.
| Last Split Date | Jun 7, 2024 |
| Split Type | Forward |
| Split Ratio | 1.29 |
Scores
Jointown Pharmaceutical Group has an Altman Z-Score of 2.26. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | n/a |